Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Nichi-Iko to Transfer More Long-Listed Original Products to Nichi-Iko sanofi-aventis
January 31, 2011
- AZ Refuses Compromise Proposed by Courts over Iressa Lawsuits
January 31, 2011
- NICE Recommends Aricept for Mild AD as Well
January 31, 2011
- 70% of Women Would Like to Be Vaccinated against Cervical Cancer
January 31, 2011
- Kowa Applies for Peretinoin in Japan
January 31, 2011
- MSD to Propose Its Own Anti-Allergy Drugs Alone or in Combination for Pollinosis
January 31, 2011
- Yasuchika Hasegawa to Step Down as JPMA President, Isao Teshirogi to Succeed
January 31, 2011
- Korosho Cautions on the Use of Botulinum Toxin Types A, B
January 31, 2011
- Dialysis Costs Kyokaikenpo ¥175 Bil. Annually
January 31, 2011
- JPMA to Finalize GL for Disclosure of Funds Offered to Medical Institutions
January 31, 2011
- PMDA to Transfer GMP Compliance Inspection Power Earlier to Prefectures
January 31, 2011
- Sanofi-aventis Signs R&D Collaboration Agreements with UCSF
January 31, 2011
- JACDS to Clarify Its Stance on Points Granted for Copayments of Dispensing Fees
January 31, 2011
- Roche Diagnostics Obtains Approval for HER2 Gene Amplification Kit
January 31, 2011
- No. of Prescriptions Filled by GROWELL Up Sharply Due to Point Granting
January 31, 2011
- Takara Bio to Globally Develop HF10 Licensed from M's Science
January 31, 2011
- Xyzal Ranked No. 1 in GP Market: RepTrack Survey
January 31, 2011
- Takeda, Kyoto Univ. to Collaborate for CNS Drug Discovery
January 31, 2011
- aRigen Licenses Novel Anti-MRSA to GCC in South Korea
January 31, 2011
- Kyowa Kirin Licenses AMG827 from Amgen
January 31, 2011
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…